Efficacy of celiprolol in the treatment of hypertension in the elderly: An open-label study

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 1, 2000, Pages 49-60

  Takeda, Kazuo ^a   Mitsunami, Kenichi ^b   Muso, Eri ^c   Kinoshita, Masahiko ^b   Sasayama, Shigetake ^c   Nakagawa, Masao ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Celiprolol; Elderly; Hyperlipidemia; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELIPROLOL; CREATINE KINASE; LACTATE DEHYDROGENASE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL;

EID: 0033998481     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)88497-0     Document Type: Article

References (22)

1. 1. SHEP (The Systolic Hypertension in the Elderly Program) Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3225-3264.
2. 2. Dahlof B, Lineholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
3. 3. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. Br Med J. 1992;304:405-412.
4. 4. Collins R, Peto R, MacMahon S, et al. Drug treatment of hypertension: An overview of the unconfounded randomised trials in the context of observation epidemiology. Lancet. 1990;335:827-838.
5. 5. Miura A, Kimura Y, Inoue K, et al. Pharmacological study with celiprolol. I. β-blocking effect, endogenous sympathetic nerve stimulating-like effect, vasodilating effect and antihypertensive effect [in Japanese]. Nihon Yakurigaku. 1990;95:191-200.
6. 6. Abe H, Yoshinaga K, Kaneko Y, et al. Study on single administration of celiprolol (NBP-582) for essential hypertension, focusing on antihypertensive effect and safety in combination with antihypertensive diuretics-results of a multiclinic open study [in Japanese] . Rinsho lyaku. 1990;6(Suppl 1):35-71.
7. 7. Otsuka K, Tsukiyama K. Effect of β-blocker celiprolol on circulation dynamics in essential hypertension-age-specific study [in Japanese]. Rinsho lyaku. 1990;6(Suppl 1):73-80.
8. 8. Kajiyama G, Horiuchi I, Matsuura H, et al. Antihypertensive effect of celiprolol (NBP-582) and effect on serum lipids [in Japanese]. Rinsho lyaku. 1990;6(Suppl l):81-94.
9. 9. Malminiemi K, Lahtera JT, Huupponen R. Effects of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension. Int J Clin Pharmacol Ther. 1995;32:156-163.
10. 10. Kurihara N, Kanayama Y, Takeda T, et al. Study on clinical effect and safety of celiprolol (NBP-582) in hypertension complicated by bronchial asthma [in Japanese]. Rinsho lyaku. 1990;6(Suppl 1): 179-195.
11. 11. Takeda K, Sasayama S, Nakagawa M, et al. Study on usefulness and serum lipid effects of long-term administration of vasodilating β-blocker celiprolol hydrochloride for essential hypertension [in Japanese], Rinsho lyaku. 1996;12:3161-3180.
12. 12. Madhavan S, Ooi WL, Cohen H, et al. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23:395-401.
13. 13. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in old Chinese patients with isolated systolic hypertension. J Hypertens. 1998;16:1823-1829.
14. 14. Gong L, Zhang W, Zhu Y, et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens. 1996;14:1237-1245.
15. 15. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
16. 16. Guidelines Subcommittee. 1999 World Health Organization/International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151-183.
17. 17. Johnson BF. The emerging problem of plasma lipid changes during antihypertensive therapy. J Cardiovasc Pharmacol. 1982;4(Suppl 2):S213-S221.
18. 18. Lijnen P. Biochemical mechanisms involved in the β-blocker-induced changes in serum lipoproteins. Am Heart J. 1992;124:549-556.
19. 19. Fogari R, Zoppi A, Pasotti C, et al. Plasma lipids during chronic antihypertensive therapy with different β-blockers. J Cardiovasc Pharmacol. 1989;14(Suppl 7):S28-S32.
20. 20. Vyssoulis GP, Karpanou EA, Pitsavos CE, et al. Differentiation of β-blocker effects on serum lipids and apolipoproteins in hypertensive patients with norrnolipidaemic or dyslipidaemic profiles. Eur Heart J. 1992;13:1506-1513.
21. 21. Yoshimaru K, Tsumura K, Yamashita N, et al. Effect of celiprolol on resting blood pressure and 24-hr heart rate in elderly hypertensives. Jpn JAppl Physiol. 1998;28:123-129.
22. 22. Hoffmann W, Hoffmann H. Results of the Austrian Celiprolol Postmarketing Surveillance Study. J Cardiovasc Pharmacol. 1986;8(Suppl 4):S88-S90.